Public Company Healthcare

Merck

Darmstadt, Hesse, Germany

Merck KGaA, commonly known as Merck Group, is a global science and technology company headquartered in Darmstadt, Germany. Its businesses span Life Science, Healthcare, and Electronics, supplying research tools, products and services for biopharmaceutical development and manufacturing, medicines and therapies, and materials for the electronics industry. In the United States and Canada, its Life Science business operates as MilliporeSigma.

Focus Areas
Life science research tools and laboratory products, Biopharmaceutical development and manufacturing solutions, Pharmaceuticals and specialty medicines

Tracked deals

3

3 tracked deals across 2025-2026.

Recent pace

2

2 tracked deals announced in the last 12 months.

Deal mix

Buyout

3 buyout

Merck Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Merck. 1 2025 ~2 est. 2 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Merck KGaA to Acquire Silence Therapeutics for Approximately $1.3 Billion
    October 19, 2026
    Buyer
    Merck KGaA
    Target
    Silence Therapeutics
    Industry
    Biotechnology
    Location
    England, United Kingdom
    Type
    Buyout

    Merck KGaA entered into a definitive agreement to acquire all outstanding shares of Silence Therapeutics in an all-cash transaction valued at approximately $1.3 billion on an equity basis. The deal is expected to close in the first quarter of 2027, subject to shareholder, court, regulatory and other customary approvals; it would add Silence’s siRNA pipeline and development capabilities to Merck’s portfolio.

  • Merck KGaA to Acquire Bio-Techne for $11.3 Billion
    June 25, 2026
    Buyer
    Merck KGaA
    Target
    Bio-Techne Corporation
    Industry
    Healthcare Services
    Location
    Minnesota, United States
    Type
    Buyout

    Merck KGaA has entered a definitive agreement to acquire Bio-Techne for $73 per share in an all-cash transaction valued at about $11.3 billion (enterprise value). The deal is expected to close in late 2026 or early 2027, subject to regulatory approvals and Bio-Techne shareholder approval.

  • Merck KGaA Acquires JSR Life Sciences Chromatography Business
    October 19, 2025
    Buyer
    Merck KGaA
    Target
    JSR Life Sciences' Chromatography Business
    Industry
    Data & Analytics
    Location
    Belgium
    Type
    Buyout

    Merck KGaA entered into a definitive agreement and later completed the acquisition of the chromatography business of JSR Life Sciences. The deal adds Amsphere Protein A resins and Protein A chromatography capabilities to Merck’s downstream Process Solutions portfolio, strengthening scalable purification for monoclonal antibodies.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 1 tracked deal by Merck. Data & Analytics Buyers & Acquisitions 1 tracked deal by Merck. Healthcare Services Buyers & Acquisitions 1 tracked deal by Merck. Acquisitions in Minnesota 1 tracked deal by Merck.

Related articles

Selling a company? Get in front of buyers like Merck

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →